PDCD1 and melanoma: In clinical practice, antibodies to PD-1 or PD-L1 rejuvenate “exhausted” T cells in TME, induce significant responses and sustained remissions, and have tolerable toxicity in patients with many types of cancer, such as lymphoma, melanoma, and mismatch repair-deficient tumours (6).